Featured Research

from universities, journals, and other organizations

Common heart failure drugs could benefit more patients, study suggests

Date:
November 28, 2012
Source:
Karolinska Institutet
Summary:
A novel study suggests that commonly used drugs to treat heart failure and high blood pressure may have a wider range of application than earlier known, and also can be used against so called HFPEF – a type of heart failure that until now has been impossible to treat. The study shows that the mortality rate in a group of HFPEF patients who used these medications decreased.

A novel study from Karolinska Institutet in Sweden suggests that commonly used drugs to treat heart failure and high blood pressure may have a wider range of application than earlier known, and also can be used against so called HFPEF -- a type of heart failure that until now has been impossible to treat. The study, which is published in the scientific journal JAMA, shows that the mortality rate in a group of HFPEF patients who used these medications decreased.

Heart failure affects 3 per cent of the overall population, and exists in two forms: reduced ability to contract the heart and reduced ability to relax the heart. The former affects younger patients, mostly men, and is treatable. The latter, called HFPEF (heart failure with preserved ejection fraction), affects older patients and women, and until now there has not been any treatment available against the disease.

In the present study, a team comprising researchers at Karolinska Institutet, Link๖ping University, and Karolinska University Hospital analysed data from about 40,000 patients from the large Swedish Heart Failure Registry. The result showed that patients with HFPEF who were treated with ACE-inhibitors or angiotensin receptor blockers -- which are commonly used drugs to lower the blood pressure -- had better survival than un-treated patients. The difference persisted after adjustment for a large number of other factors, such as patient age, general health and other factors, and the final decrease in mortality was 10 per cent.

In heart failure, stress hormones are secreted that are damaging to the heart in the long term, and ACE-inhibitors and angiotensin receptor blockers both work to stop the adverse effects of these hormones. In previous randomized studies, the drugs have not proven effective against HFPEF, but the researchers behind the current finding suggest that earlier studies may have been too small to detect a benefit. At the same time they point out that because their study was not randomized, further research is needed to confirm these novel results.

"However, the large number of patients and the extensive statistical adjustments suggest a strong likelihood of a benefit from ACE-inhibitors and angiotensin receptor blockers," says Docent Lars Lund of Karolinska Institutet, who led the study. "One might also add that these drugs are in comparison not that expensive."

The work was financed by the Swedish Heart Lung Foundation, the Stockholm County Council and the Swedish Association of Local Authorities and Regions.


Story Source:

The above story is based on materials provided by Karolinska Institutet. Note: Materials may be edited for content and length.


Journal Reference:

  1. Lars H. Lund, Lina Benson, Ulf Dahlstr๖m, Magnus Edner. Association Between Use of Renin-Angiotensin System Antagonists and Mortality in Patients With Heart Failure and Preserved Ejection FractionRenin-Angiotensin System Antagonists and Mortality. JAMA: The Journal of the American Medical Association, 2012; 308 (20): 2108 DOI: 10.1001/jama.2012.14785

Cite This Page:

Karolinska Institutet. "Common heart failure drugs could benefit more patients, study suggests." ScienceDaily. ScienceDaily, 28 November 2012. <www.sciencedaily.com/releases/2012/11/121128093611.htm>.
Karolinska Institutet. (2012, November 28). Common heart failure drugs could benefit more patients, study suggests. ScienceDaily. Retrieved September 22, 2014 from www.sciencedaily.com/releases/2012/11/121128093611.htm
Karolinska Institutet. "Common heart failure drugs could benefit more patients, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/11/121128093611.htm (accessed September 22, 2014).

Share This



More Health & Medicine News

Monday, September 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) — Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com
Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) — Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) — A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) — The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins